Division of Gynecologic Oncology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
Gynecol Oncol. 2012 Dec;127(3):532-7. doi: 10.1016/j.ygyno.2012.08.026. Epub 2012 Aug 30.
The aim of this study was to determine the rate of occult metastasis, including isolated tumor cells, in para-aortic lymph nodes of patients with stage IIIC1 endometrial cancer who underwent pelvic and para-aortic lymphadenectomy.
A series of 15 patients who had undergone combined pelvic and para-aortic lymphadenectomy during the period from 2004 to 2010 and who were diagnosed as being positive for pelvic node metastasis but negative for para-aortic node metastasis were included in this study. Ultra-staging by multiple slicing, staining with hematoxylin/eosin and cytokeratin, and microscopic inspection was performed on a total of 242 para-aortic lymph nodes.
Eleven (73.3%) of the 15 patients had occult para-aortic lymph node metastasis. Two patients (13.3%) had macrometastasis and nine patients (60.0%) had isolated tumor cells. Type 2 endometrial cancer tended to have a higher rate of occult metastasis than that of type 1 cancer (90% vs. 40%, P=0.07). The rate of occult para-aortic node metastasis was not related to the number of metastatic pelvic nodes. Five patients suffered recurrence in the lung or in the intraabdomen, but lymph node recurrence was not found in any case.
Patients with stage IIIC1 endometrial cancer have a potentially high rate of occult para-aortic node metastasis. Local treatment of the para-aortic region should be considered in patients with stage IIIC1 endometrial cancer until effective adjuvant therapy is established.
本研究旨在确定行盆腔和腹主动脉淋巴结切除术的 IIIC1 期子宫内膜癌患者中,存在隐匿性转移(包括孤立肿瘤细胞)的腹主动脉淋巴结的发生率。
回顾性分析 2004 年至 2010 年间接受联合盆腔和腹主动脉淋巴结切除术的 15 例患者的临床资料,这些患者盆腔淋巴结转移阳性但腹主动脉淋巴结转移阴性。对 242 个腹主动脉淋巴结进行多切片、苏木精/伊红和细胞角蛋白染色以及显微镜检查的超分期。
15 例患者中有 11 例(73.3%)存在隐匿性腹主动脉淋巴结转移。2 例(13.3%)患者存在大转移灶,9 例(60.0%)患者存在孤立肿瘤细胞。2 型子宫内膜癌的隐匿性转移率高于 1 型(90%比 40%,P=0.07)。隐匿性腹主动脉淋巴结转移的发生率与盆腔淋巴结转移的数量无关。5 例患者出现肺或腹腔内复发,但未发现淋巴结复发。
IIIC1 期子宫内膜癌患者存在潜在的高隐匿性腹主动脉淋巴结转移率。对于 IIIC1 期子宫内膜癌患者,应考虑局部治疗腹主动脉区域,直到建立有效的辅助治疗。